FIELD: biotechnologies.
SUBSTANCE: invention relates to cell technologies. Method of improving cardiac function in mammal is described, involving: transplantation of cardiomyocytes into myocardium said mammal, wherein said cardiomyocytes contain first expression vector, containing first sequence of nucleic acid, coding R1 subunit of ribonucleotide reductase, and second expression vector, containing second sequence of nucleic acid, coding R2 subunit of ribonucleotide reductase, wherein said first and second nucleic acid sequences are functionally connected with promoter, which induces hyperexpression of R1 and R2, which provides formation of deoxy-ATP and improvement of cardiac function in mammal.
EFFECT: invention broadens capabilities of cardiac failure treatment.
27 cl, 40 dwg, 15 tbl, 51 ex
Title | Year | Author | Number |
---|---|---|---|
APPLICATION OF EDG2 RECEPTOR ON MODEL OF CARDIO-VASCULAR COLLAPSE IN ANIMALS | 2003 |
|
RU2337963C2 |
PHARMACOLOGICAL COMPOSITION FOR COMPENSATION OF ARTERIAL HYPERTENSION AND ASSOCIATED PATHOLOGIES OF THE CARDIOVASCULAR SYSTEM | 2021 |
|
RU2792884C1 |
COMPOSITION FOR TREATING ARTERIAL HYPERTENSION AND CARDIOVASCULAR PATHOLOGIES ASSOCIATED THEREWITH | 2019 |
|
RU2734281C1 |
TREATING HEART FAILURE | 2020 |
|
RU2824501C2 |
METHOD OF SIMULTANEOUS REGISTRATION OF NaDEPENDENT Ca FLOWS AND FUNCTIONAL STATE OF WHOLE ISOLATED HEART IN EXPERIMENT | 2009 |
|
RU2400825C1 |
SYSTEM DELIVERY AND REGULATED EXPRESSION OF PARACRINE GENES FOR TREATMENT OF CARDIOVASCULAR AND OTHER DISEASES | 2013 |
|
RU2642605C2 |
METHOD FOR PREVENTING THE DEVELOPMENT OF MYOCARDIAL INFARCTION IN MICE WITH MELANOMA THAT DEVELOPED AGAINST THE BACKGROUND OF CHRONIC NEUROGENIC PAIN | 2022 |
|
RU2786322C1 |
AGENT HAVING CARDIOTONIC ACTIVITY | 2012 |
|
RU2521213C1 |
METHOD FOR PREVENTING ANTHRACYCLINE CARDIOTOXICITY IN PATIENTS WITH BREAST CANCER | 2014 |
|
RU2546399C1 |
AGENT AGAINST MYOCARDIAL HYPOXIA | 2013 |
|
RU2522953C1 |
Authors
Dates
2017-01-27—Published
2012-05-29—Filed